Metrics as of 10/13/2026, 06:54 PM (Berlin time), refresh in progress.
Alamar Biosciences Stock
Alamar Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Yuling Luo
- Employees
- 222
- Market cap
- $1.8 B
- IPO
- 17/04/2026
Alamar Biosciences, Inc. is a healthcare company in the biotechnology industry based in Fremont, US. The company operates as a commercial-stage proteomics firm specializing in the highly sensitive and simultaneous identification of various proteins for both scientific research and prospective medical applications.…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Alamar Biosciences stock: price history
1D
+8.5%
1W
-8.1%
1M
-8.8%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Ask the agents about Alamar Biosciences
Analyst assessment of Alamar Biosciences
PRICE TARGET LOW
US$32.00
CONSENSUS
US$33.50
MEDIAN
US$33.50
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 11/08/2026
Alamar Biosciences stock metrics
P/E
-48.13
P/B
4.78
EV/EBITDA
-53.7
RETURN ON EQUITY
-4.2%
NET MARGIN
-44.9%
DEBT/EQUITY
0.16
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
52.1%
FLOAT SHARES
36,083,403
AVG. DAILY VOLUME (30D)
593,159
Insider transactions (SEC)
Brottem John L.
RAGUSA ROBERT P
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +8.5%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Alamar Biosciences stock
What does Alamar Biosciences do?
Alamar Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Yuling Luo, the company employs around 222 people.
The IPO was on 17/04/2026; the stock trades on NASDAQ under the ticker ALMR.
What do analysts say about Alamar Biosciences stock?
2 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$33.50, ranging from US$32.00 to US$35.00, with a median of US$33.50.
This is an external assessment, not a statement by Market Jury.
Does Alamar Biosciences pay a dividend?
No, Alamar Biosciences currently does not pay a dividend.
Which stocks are comparable to Alamar Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Alamar Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Alamar Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.